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and Heikki A. Koistinen3,4,5,*1University of Helsinki,
Molecular Systems Biology
Research Group and
Proteomics Unit, Institute of
Biotechnology, 00014
Helsinki, Finland
2University of Helsinki, Drug






Haartmaninkatu 4, PO BOX











Skeletal muscle insulin resistance is a central defect in the pathogenesis of type 2
diabetes (T2D). Here, we analyzed skeletal muscle proteome in 148 vastus later-
alis muscle biopsies obtained from men covering all glucose tolerance pheno-
types: normal, impaired fasting glucose (IFG), impaired glucose tolerance (IGT)
and T2D. Skeletal muscle proteome was analyzed by a sequential window acqui-
sition of all theoretical mass spectra (SWATH-MS) proteomics technique. Our
data indicate a downregulation in several proteins involved in mitochondrial elec-
tron transport or respiratory chain complex assembly already in IFG and IGTmus-
cles, with most profound decreases observed in T2D. Additional phosphoproteo-
mic analysis reveals altered phosphorylation in several signaling pathways in IFG,
IGT, and T2D muscles, including those regulating glucose metabolic processes,
and the structure of muscle cells. These data reveal several alterations present
in skeletal muscle already in prediabetes and highlight impairedmitochondrial en-
ergy metabolism in the trajectory from prediabetes into T2D.
INTRODUCTION
The prevalence of type 2 diabetes (T2D) has reached epidemic proportions worldwide. As a chronic meta-
bolic disease, T2D contributes to increased morbidity and mortality, leading to increased economic strain
on health care as well as human suffering (Zheng et al., 2017; Unnikrishnan et al., 2017). Despite intensive
efforts, currently available methods to prevent and treat T2D are far from optimal, and a significant propor-
tion of patients doesnot meet treatment goals (Unnikrishnan et al., 2017, American Diabetes Association,
2018). Thus, more research is urgently needed to understand the pathogenesis of T2D in more detail.
Beyond its obvious role in locomotion, skeletal muscle is themain site of glucose uptake and accounts for80%
of total insulin-stimulated glucose disposal (Defronzo et al., 1981; Defronzo et al., 1985). Skeletal muscle insulin
resistance is a central and early defect in the pathogenesis of T2D (Eriksson et al., 1989, 1992; Cline et al., 1999;
Defronzo et al., 1985). Therefore, detailed knowledge about the factors regulating insulin action in muscle is
likely to improve the treatment of people with insulin resistance, and help prevent the development of T2D.
Toget further insight into the roleof the skeletalmuscle in thepathogenesis of T2D,wehavepreviously obtained
vastus lateralis skeletal muscle biopsies from 271 Finnish individuals spanning all glucose tolerance phenotypes
(normal glucose tolerance [NGT], impaired fastingglucose [IFG], impairedglucose tolerance [IGT], and T2D sub-
jects) (Scott et al., 2016). We have profiled their muscle transcriptome with high-depth strand-specific mRNA
sequencing and performed dense array-based genotyping. We found that the expression of several different
genegroups, such as genes involved in ER protein localization or cellular respiration, was decreased in T2Dmus-
cles (Scott et al., 2016). Theobserveddecrease in genes involved in cellular respiration is in goodagreement with
earlier studies onmuscle transcriptome that demonstrated decreased expression of genes regulating oxidative
metabolism and mitochondrial function in insulin resistance and T2D (Mootha et al., 2003; Patti et al., 2003).
Taken together, studies on carefully characterized humans exhibiting normal, prediabetic as well as diabetic
glucosemetabolism, are powerful approaches to reveal important and novelmechanisms contributing to insulin
resistance and T2D.
Genes function as building instructions to proteins which ultimately regulate and carry out cellular func-
tions. As alterations in mRNA expression may not be accurately reflective of the respective proteiniScience 24, 102712, July 23, 2021 ª 2021 The Author(s).





Articleconcentration (Edfors et al., 2016), it is crucial to analyze potential differences in protein expression be-
tween the different glucose tolerance phenotypes to get insight into the potential causes leading to meta-
bolic alterations. To this end, several relatively small studies, with 6–11 individuals per different phenotype
(e.g., lean, obese, and type 2 diabetic), have used proteomics techniques. These studies have revealed
important differences in skeletal muscle of insulin resistant individuals, such as an increase in expression
of proteins involved in glycolysis, a decrease in mitochondrial proteins, and alterations in muscle structural
proteins (Højlund et al., 2003; Hwang et al., 2010; Giebelstein et al., 2012; Chae et al., 2018). However, a
shortcoming in the previous studies on skeletal muscle proteome may have been limited proteome
coverage, as for example the most expressed proteins, such as contractile proteins, have been quantified,
while the low-abundance regulatory proteins have remained undetected (Deshmukh, 2016). The recent
development of quantitative proteomic techniques using liquid chromatography-tandem mass spectrom-
etry combined with enhanced bioinformatic analyses has enabled deeper coverage of the proteome
(Deshmukh, 2016; Loukovaara et al., 2015). This advance in the field is crucial for understanding the com-
plex molecular interactions at tissue level that predispose to insulin resistance.
Most proteomic studies have been analyzed using data-dependent acquisition (DDA) method where a
selected number of peptides are sequentially selected for MS2 analysis. However, the stochastic precursor
selection of DDA can lead to inconsistent detection of peptides and the corresponding proteins in the sam-
ple cohort, resulting in many missing values in the data (Gillet et al., 2012; Krasny and Huang, 2021). In the
present study, we have analyzed 148 skeletal muscle proteomes from men who cover all glucose tolerance
phenotypes: NGT, IFG, IGT, as well as T2D, using a data-independent acquisition method, a sequential
window acquisition of all theoretical mass spectra (SWATH-MS) proteomics technique (Gillet et al., 2012;
Krasny and Huang, 2021). SWATH-MS is an emerging mass spectrometric method that offers a high degree
of quantitative accuracy, proteomic coverage, reproducibility of proteome coverage, and sample
throughput, as well as a low number of missing values. Our data indicate a strong downregulation in several
proteins involved in mitochondrial electron transport or respiratory chain complex assembly already in IFG
and IGT muscles, with most profound decreases observed in T2D. These data highlight impaired mito-
chondrial energy metabolism in the trajectory from prediabetes into T2D.
RESULTS
SWATH-MS-based quantitative analysis of human muscle samples
We obtained vastus lateralis skeletal muscle biopsies from 148 men whose glucose tolerance covered all
phenotypes from normal to T2D (Table 1), and we performed extensive proteome profiling of the muscle
samples using label-free quantitative SWATH-MS proteomic analysis. The workflow used is shown in Fig-
ure 1A. Type 2 diabetic men had good glycemic control and they were slightly older than men with normal
glucose tolerance. Men with IGT or T2D had higher body weight and had a significantly greater BMI
compared to normal glucose tolerant men (Table 1).
The SWATH-MS data analysis depends on a reference assay library, which must be sample-specific and be
of sufficient compositional depth to enable extensive peptide identification. Therefore, a muscle-sample-
specific reference spectral library was first generated by DDA analysis of the six fractionated muscle sam-
ples that covered all glucose tolerance phenotypes: NGT (n = 2), a combination of IFG and IGT (n = 1), and
T2D (n = 3). This resulted in a spectral library consisting of 3,096 human proteins. In quantitative SWATH-MS
experiments, a total of 2,026 human proteins were identified and quantified across all samples (see Table
S1). The most abundant proteins in samples are typical sarcomere proteins, such as actins, myosins, tropo-
myosins, and titin. The identified proteins were associated with typical muscle functions, such as oxidation-
reduction, cell-cell adhesion, translation, muscle contraction, and mitochondrial electron transport (Fig-
ure 1B). In addition, the subcellular localization of the identified proteins was a characteristic of muscle tis-
sue (Figure 1C), including mitochondria, cytosol, sarcomere, and sarcolemma. This corresponds well with
the fact that skeletal muscle proteins are compartmentalized in different compartments including micro-
some, sarcolemma, cytosol, contractile apparatus, and mitochondria (Ohlendieck, 2011).
Comparative proteomics contrasting all glucose tolerance phenotypes
To get an overall view of protein profiles of the skeletal muscle samples in different glucose tolerance phe-
notypes, we performed hierarchical clustering of all quantified proteins based on the abundance of the
proteome profile (Figure 2A). Most prediabetes or T2D samples accumulated on the other side of the
dendrogram, in separate from samples with normal glucose tolerance. A similar result was seen in principal2 iScience 24, 102712, July 23, 2021
Table 1. Male volunteers participating in the study
NGT (n = 85) IFG (n = 25) IGT (n = 14) T2D (n = 24)
Age (y) 51 G 1 53 G 2 55 G 2 57 G 2a
Weight (kg) 83.1 G 1.6 86.5 G 3.1 97.6 G 2.8b 95.4 G 3.1b
Height (cm) 180 G 1 178 G 1 180 G 2 179 G 1
BMI (kg/m2) 25.7 G 0.4 27.3 G 0.8 30.3 G 1.1b 29.8 G 1.0c
Waist (cm) 95 G 1 100 G 2 108 G 3c 106 G 3c
Hip (cm) 99 G 1 100 G 1 106 G 2b 103 G 1
WHR 0.95 G 0.01 0.99 G 0.01 1.02 G 0.02b 1.03 G 0.02c
fB-glucose (mmol/L) (n) 5.3 G 0.08 (24) 5.4 G 0.2 (10) 5.0 G 0.3 (5) 6.7 G 0.3c,d,e (11)
fP-glucose (mmol/L) (n) 5.5 G 0.05 (61) 6.3 G 0.2 b (15) 6.3 G 0.2 a (9) 7.6 G 0.4 c,d,e (13)
HbA1c (%) 5.3 G 0.03 5.4 G 0.07 5.6 G 0.09 6.3 G 0.12
c,d,e
HbA1c (mmol/mol) 35 G 0.3 35 G 0.8 37 G 1.0 45 G 1.3
c,d,e
Fasting serum insulin (mU/l) 8 G 1 13 G 2 a 18 G 2 c 18 G 3 c
Fasting serum cholesterol (mmol/L) 4.4 G 0.1 4.4 G 0.1 4.3 G 0.2 4.1 G 0.2
Fasting serum triglycerides (mmol/L) 1.2 G 0.1 1.3 G 0.1 1.8 G 0.2 b 1.5 G 0.1 a
Fasting serum HDL cholesterol (mmol/L) 1.4 G 0.03 1.3 G 0.05 1.1 G 0.05 c 1.2 G 0.05
Fasting serum LDL cholesterol (mmol/L) 1.7 G 0.05 1.7 G 0.06 1.7 G 0.14 1.5 G 0.09
HOMA-IR 1.4 G 0.1 2.6 G 0.4 a 3.4 G 0.5 c 4.2 G 0.6 c,f
Data are given as mean G SEM, one-way ANOVA followed by Sidak’s post hoc test for multiple comparisons.
ap < 0.05 vs NGT.
bp < 0.01 vs NGT.
cp < 0.001 vs NGT.
dp < 0.001 vs IFG.
ep < 0.001 vs IGT.




Articlecomponent analysis that showed some grouping of samples. However, no clear difference between sample
types could be observed (see Figure S1). In spite of a high similarity in the protein profiles at the individual
level, differences were detected between sample groups. The unique protein profile of each glucose toler-
ance category was visualized by a heatmap of the average of protein abundance in different sample groups
(Figure 2B).
Because we detected mean differences in prediabetes and T2D proteomes compared with NGT pro-
teomes, we next performed one-way ANOVA analysis to find the proteins that are present in significantly
altered concentrations in the different glucose tolerance sample groups. In comparison with NGT samples,
the relative abundance of 95 and 67 proteins was significantly altered (q < 0.05) in IFG and IGT samples,
respectively (Figure 2C and Table S2). However, more profound changes in the proteome were detectable
in T2D samples, where 420 proteins were significantly changed when compared with NGT. The changes in
protein abundance aremainly moderate and decreasing relative to NGT, as shown in heatmap in Figure 2B.
Biological processes behind differentially expressed proteins
When the proteomes of prediabetic IFG and IGT were compared with NGT, the majority of the altered pro-
teins were found to be reduced (Figure 3). Only one protein in IFG comparison and nine proteins in IGT
comparison were upregulated in prediabetic condition. To understand the functional association of these
altered proteins, the proteins were classified as per their involvement in different biological processes and
KEGG pathways using DAVID bioinformatics resources (Figure 3). The muscle library was used here as a
background database. Our data indicate a strong downregulation in mitochondrial energy metabolism
in IFG and IGT samples because several proteins involved in mitochondrial electron transport (11 proteins
in IFG and 13 in IGT) or mitochondrial respiratory chain complex I assembly (11 proteins in IFG and 12 in
IGT) were decreased when compared with NGT. In addition, KEGG pathway analysis revealed a downre-
gulation of oxidative phosphorylation (22 proteins in IFG and 31 in IGT) and other pathways related to en-




Figure 1. Quantitative SWATH-MS analysis of human muscle samples
(A) Muscle biopsies were collected from 148 men whose glucose tolerance covered all phenotypes from normal to type 2
diabetes. Muscle proteins were extracted and digested with trypsin. For spectral library generation, the resulting
peptides were fractionated and analyzed using data-dependent acquisition mode (DDA). The spectral library built was
then used to extract the peptide and the quantification information of the SWATH runs. In addition, six samples from each
glucose tolerance group were subjected to phosphopeptide analysis. Statistical analysis and bioinformatics approaches
were used to understand the biological relevance of the differentially expressed proteins.
(B and C) (B) The DAVID bioinformatics tool was used to classify all 2,026 identified proteins as per their biological




ArticleMore differences in proteome level were detected when T2D samples were compared with NGT (Fig-
ure 4). Similarly, the expression levels of the most proteins were reduced relative to NGT, but we
could also detect a group of proteins with higher abundance. The downregulated proteins were
strongly associated with energy metabolism as seen in GO enrichment and KEGG pathway analysis.
We could detect a decrease in several proteins involved in aerobic respiration, such as tricarboxylic
acid cycle (the citric acid cycle, 19 proteins) and the electron transport system (32 proteins), as well
as proteins linked to branched-chain amino acid catabolism (10 proteins). Interestingly, many proteins
with oxidoreductase activity involved in oxidation-reduction (redox) processes (45 proteins) were also
found to be decreased in T2D. Redox equilibrium is essential for cellular homeostasis, being a key4 iScience 24, 102712, July 23, 2021
A
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Figure 2. Changes in skeletal muscle proteome in different glucose tolerance phenotypes
(A) Hierarchical clustering of all quantified proteins based on the abundance of the proteome profile.
(B) In the Z-score heatmap the expression levels of all 2,026 quantified proteins are shown as themean of the SWATH peak
area for each sample group.
(C) Venn diagrams showing the overlap between significantly different proteins in IFG, IGT, and T2D proteomes
compared with NGT proteome. The number in brackets indicates how many proteins were significantly altered (q < 0.05)




Articlemodulator of skeletal muscle plasticity/dysfunction in response to exercise or metabolic diseases (Es-
pinosa et al., 2016).
A total 18 upregulated proteins were also detected in T2D samples. These proteins were involved inmuscle
filament sliding (7 proteins) and muscle contraction (5 proteins). These muscle function proteins, including
myosin (MYH2, MYH3, MYL1), tropomyosin (TPM1, TPM2), and troponin 1 (TNNI2), were all slightly upre-
gulated in T2D samples, indicating that type 2 diabetic metabolism affects muscle structure and function
(Figure 4).
Oxidative phosphorylation
Proteomics analysis of skeletal muscle samples from different glucose tolerance phenotypes revealed
changes in energy metabolic processes, especially in oxidative phosphorylation (OXPHOS, Figure 5).
Oxidative phosphorylation is a highly efficient metabolic pathway to produce large amounts of ATP. In
this process, electrons from NADH or FADH2 are transferred to O2 simultaneously pumping protons out
from the mitochondrial matrix by a set of enzymes which is called the electron transport chain (complexes
I to IV). In the final step, ATP is synthesized when protons flow back to themitochondrial matrix through ATP
synthase (complex V). All complexes of the respiratory chain consist of several subunits, and we observed a
decrease in the several different subunits (Figure 5). Some changes were apparent already in prediabetic
conditions, but the most obvious changes were seen in T2D samples. Especially, 31 subunits of 50 in com-
plex I (NADH dehydrogenase) and 7 subunits of 11 in complex III (cytochrome c reductase) were downre-
gulated in T2D samples. In addition, a number of subunits of both F1 and F0 domains of ATP synthase were
reduced in T2D samples compared with the NGT group. These data are consistent with previousiScience 24, 102712, July 23, 2021 5
Figure 3. Comparison between prediabetes and NGT proteomes
The volcano plots of differentially expressed muscle proteins between IFG and NGT (left panel) or IGT and NGT (right panel). p-value was set to match q-
value < 0.05. The light blue dots indicate significantly down-regulated proteins with FC < 2, and the blue dots with FC > 2. The red dots indicate significantly
up-regulated proteins. Down-regulated proteins in the prediabetes samples were categorized according to their biological processes and KEGG pathways




Articleobservations regarding obese and type 2 diabetic skeletal muscle (Højlund et al., 2003; Hwang et al., 2010;
Giebelstein et al., 2012; Chae et al., 2018). Reduced OXPHOS gene expression has been observed also in
skeletal muscle in people with IGT (Osler et al., 2015; Mootha et al., 2003).Phosphorylation in skeletal muscle proteome
To complement the quantitative results, we characterized the general phosphorylation events in a subset of skel-
etal muscle samples representing all different glucose tolerance phenotypes (6 men in each glucose tolerance
group NGT, IFG, IGT, and T2D) using phosphoproteomic analysis. We identified a total of 2722 distinct phos-
phorylated amino acids in 708 phosphoproteins (see Table S3), indicating that several proteins were phosphor-
ylated at multiple sites. A large proportion of the identified phosphopeptides originated from highly abundant
myofibrillar proteins. This is in agreement with previous publications that demonstrate that sarcomeric proteins
are overrepresented in phosphoanalysis (Højlund et al., 2009; Potts et al., 2017). For example, in our study, the
protein with the most phosphorylation sites was titin, in which we identified 384 distinct phosphorylation sites.
This result is not unexpected because titin is a giant protein that contributes to approximately 16% of the total
protein mass in skeletal muscle (Deshmukh et al., 2015). Moreover, titin is highly phosphorylated: more than 960
phosphosites in human titin are reported in the PhosphoSitePlus database (www.phosphosite.org). Other6 iScience 24, 102712, July 23, 2021
Figure 4. Comparison between type 2 diabetes and NGT proteomes
The volcano plots of differentially expressed muscle proteins between T2D and NGT. p-value was set to match q-value <
0.05. The light blue dots indicate significantly down-regulated proteins with FC < 2 and the blue dots with FC > 2. The red
dots indicate significantly upregulated proteins. Downregulated and upregulated proteins in the T2D samples were
categorized as per their biological processes and KEGG pathways using DAVID bioinformatics tool. The most significant




Articlesarcomere proteins with multiple phosphorylated sites, such as myosins (225 distinct phosphosites), actins (19
phosphosites), and tropomyosins (34 phosphosites), were also detected.
Next, we compared these identified phosphosites in samples from men with prediabetic IFG and IGT, or
T2D with samples from men with normal glucose tolerance to identify the skeletal muscle proteins where
phosphorylation is altered during progression to diabetes. We identified 388, 335, and 298 phosphosites
that exhibited a major alteration in abundance (p-value < 0.05, or observed only in another condition) in
IFG, IGT, and T2D sample groups, respectively (Figure 6A). These phosphosites were linked to 213, 197,
and 183 different phosphoproteins, respectively (Figure 6B). KEGG pathway overrepresentation analysis
of these proteins with altered phosphorylation revealed an enrichment of signaling pathways regulatingiScience 24, 102712, July 23, 2021 7
Figure 5. Oxidative phosphorylation is downregulated in skeletal muscle in prediabetes and type 2 diabetes
The oxidative phosphorylation system (OXPHOS) of the mitochondrial inner membrane is composed of five enzymes
(respiratory complexes I–V). All respiratory enzymes consist of several subunits (the total number of subunits shown in the
table), and we observed a decrease in most subunits already in prediabetes (IFG, IGT). Number of proteins with significant




Articleglucose metabolic processes, muscle contraction, and the structure of muscle cells, correlating well with
SWATH-quantification results (see Table S4). Alterations were identified in the glycolysis/gluconeogenesis
and insulin signaling pathway events. Interestingly, a clear change in phosphorylation was already evident
in IFG, indicating that changes in skeletal muscle are already evident at an early stage in dysregulated
glucose metabolism.
To investigate which kinases controlled the phosphorylation of proteins in T2D samples, we used Networ-
KIN software, which combines protein-associated network and preferred recognition motif information to
predict the likelihood of kinase-substrate relationships (Horn et al., 2014). This analysis predicted a kinase in
115 of 298 detected phosphosites in T2D samples (Figure 6C). The analysis revealed a very high prediction
for protein kinase C (PKC) kinases (PKCa, PKCb, PKCd, PKCε, PKCg), regulating a total of 39 substrate phos-
phosites. Also casein kinases (CK) 1 and 2 were heavily enriched, having 17 substrate sites. In addition, the
NetworKIN algorithm predicted Ca2+/calmodulin-dependent protein kinase II, (CaMKII), cyclin-dependent
kinases (CDKs), myotonin-protein kinase (DMPK), CLK, and MAPKs as likely candidates involved in the dia-
betes process. The more detailed analysis of the phosphorylation of these kinase substrates indicates that
many kinases were less active in diabetes samples compared with NGT samples (Figure 6D). For example,





Figure 6. Phosphorylation in skeletal muscle proteome
(A and B) Venn diagram representing the number of phosphosites (A) or phosphoproteins (B) with a significant change in
abundance (p-value < 0.05, or observed only in another condition) in the IFG, IGT and T2D sample groups compared with
NGT.
(C) NetworKIN software was used to predict kinases that are dysregulated in type 2 diabetes. 298 phosphorylated sites
that exhibited an alteration in abundance in T2D samples were used as input. A total of 20 distinct kinase families
associated with 115 phosphorylated sites was predicted. The numbers indicate the total number of phosphorylation sites
linked to the specific kinases.
(D) The more specific details about NetworKIN predicted kinase substrates. All the substrates listed here have significant
differences between T2D and NGT samples. Red spot means that the substrate is phosphorylated more in T2D samples,
indicating more active kinases in T2D. Blue spot indicates more active kinase in NGT samples (more phosphorylation in
NGT samples). Some substrate proteins have multiple regulated phosphorylation sites (in sequence order in the figure).
Phosphosites are indicated in Table S3.
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Figure 7. Unique differentially expressed proteins
Box-and-whisker plots of differentially expressed individual proteins that displayed a significantly different abundance
(q < 0.05) in the prediabetic or T2D samples compared with the NGT samples. Box-and-whisker plots indicate median and
interquartile range; the whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile
range from the box. ATP-dependent RNA helicase SUPV3L1 protein expression was uniquely reduced in IFG muscles.
Small nuclear ribonucleoprotein-associated protein N (SNRPN) expression was uniquely downregulated in IGT muscles.
ATP synthase subunit a (MT-ATP6), NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (NDUFAF6) and
tubulin-folding cofactor B (TBCB) were significantly downregulated only in T2D muscles. * = q < 0.05; ** = q < 0.01, ns =





Articlenot detectable at all in T2D samples. Similarly, many substrates of PKB and CaMKII were less phosphory-
lated in T2D samples. On the other hand, based on NetworKIN analysis, more active kinases, such as PKCε,
were also detected. PKCε phosphorylates sarcomere proteins, such as myosins and titin, indicating a reg-
ulatory role in contractile function and the structure of muscles. We also observed a slight increase in the
activity of CDK kinases in T2D samples.Changes in proteome with aging
We had the opportunity to analyze skeletal muscle proteome in paired muscle biopsies obtained several
years apart from two men: one man with NGT (7-year interval) and one man with T2D (9-year interval).
Expression of 20 proteins was upregulated in both men as they were elderly (see Table S5). The Jupiter
microtubule-associated homolog 1 (JPT1) protein abundance increased 185-fold in T2D muscle during




ArticleUnique differentially expressed proteins
We identified interesting individual proteins that displayed a significant decrease (q < 0.05) when
comparing the prediabetic or T2D samples with the NGT samples (Figure 7). ATP-dependent RNA helicase
SUPV3L1, mitochondrial (SUPV3L1) regulates mitochondrial RNA metabolism and it also unwinds dsDNA
(Minczuk et al., 2002; Szczesny et al., 2010). SUPV3L1 protein expression was uniquely reduced in IFG mus-
cles (3.9 times less compared with NGT). Small nuclear ribonucleoprotein-associated protein N (SNRPN) is
a part of the spliceosome, and it regulates pre-mRNA processing and may be involved in tissue-specific
alternative splicing (Jing et al., 2015). SNRPN expression was uniquely downregulated in IGT muscles (3
times less compared with NGT). ATP synthase subunit a (MT-ATP6) is a part of the mitochondrial mem-
brane ATP synthase (complex V) (Ganetzky et al., 2019). NDUFAF6 is crucial in the assembly of mitochon-
drial NADH:ubiquinone oxidoreductase complex (complex I) (Pagliarini et al., 2008, Mckenzie et al., 2011),
and tubulin-folding cofactor B regulates tubulin synthesis (Tian et al., 1997). The expression of MT-ATP6
(4.3 times less compared with NGT), NDUFAF6 (2.8 times less compared with NGT), and tubulin-folding
cofactor B (2.6 times less compared with NGT) was uniquely downregulated in T2D muscles.Multiple linear regression analysis
Multiple linear regression was used to estimate the effect of the subjects’ glucose tolerance status, age,
HOMA-IR (log2), and physical activity level on protein intensities (see Table S6). The regression model
reached overall significance (F-test q < 0.05) for 524 proteins, with the highest number of proteins affected
by glucose tolerance status and physical activity level (200 and 143 proteins, respectively; q < 0.05), while
age and HOMA-IR contributed to only a few of the proteins (3 and 5 proteins, respectively; q < 0.05). The
proteins affected by glucose tolerance status and physical activity level were mostly different, with an over-
lap of 29 proteins (see Figure S2). Galectin-1 (LGALS1) was increased with increasing HOMA-IR and
decreased by increasing physical activity level (q < 0.0001 for both). Glyceraldehyde-3-phosphate dehydro-
genase (q < 0.01), glycogen debranching enzyme (AGL, q < 0.01), and L-lactate dehydrogenase A chain
(q < 0.05) were increased with increasing HOMA-IR, whereas D-beta-hydroxybutyrate dehydrogenase,
mitochondrial (q < 0.01) was decreased with increasing HOMA-IR, independent of other variables in the
model.
Glycogen synthase levels were decreased by worsening of glucose tolerance status from NGT, IFG, IGT to
T2D, independent of other variables in the model (q < 0.01). Moreover, concentrations of many proteins
involved in mitochondrial energy metabolism such as isocitrate dehydrogenase [NAD] subunit beta, mito-
chondrial (IDH3B) (q < 0.01), NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mito-
chondrial (NDUFA10) (q < 0.01), and ATP synthase subunit a (MT-ATP6) (q < 0.01) were decreased by wors-
ening of glucose tolerance status, with no statistically significant contribution by other variables in the
model.
There were also mitochondrial proteins that were impacted by both glucose tolerance, as well as physical
activity level. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 (NDUFB3) and NADH de-
hydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 (NDUFA2) were downregulated by worsening
glucose tolerance (q < 0.05 and q < 0.01, respectively) and increased by level of physical activity (q <
0.0001 for both), independent of age and HOMA-IR. Citrate synthase, mitochondrial (CS) was also
decreased by worsening glucose tolerance (q < 0.05) and increased by physical activity level (q < 0.05)
with no statistically significant contribution by other variables in the model (see Table S6).DISCUSSION
Skeletal muscle insulin resistance is a central and early defect in the pathogenesis of T2D (Eriksson et al.,
1989, 1992; Cline et al., 1999). Therefore, detailed knowledge about regulation of insulin action in muscle is
likely to improve treatment of people with insulin resistance and help prevent the development of T2D.
Here, we report skeletal muscle proteome in 148 vastus lateralis muscle biopsies obtained from men
covering all glucose tolerance phenotypes: from normal glucose tolerance, IFG, IGT, and T2D. To the
best of our knowledge, this is to date the largest proteomic analysis of human skeletal muscle.
Our results indicate a strong downregulation in proteins involved in mitochondrial energy metabolism and
oxidative phosphorylation in prediabetic (IFG and IGT) as well as T2D samples. We observed a decrease in




Articlealso in prediabetic conditions. However, the most obvious changes were seen in T2Dmuscle samples. Mul-
tiple linear regression analysis revealed an independent contribution of worsening of glucose tolerance
status to the decrease in intensities of many proteins involved in mitochondrial energy metabolism. There
were also mitochondrial proteins where both worsening of glucose tolerance (a decrease) and increase in
physical activity level (an increase) contributed to protein intensities. HOMA-IR contributed significantly to
only a few protein intensities in skeletal muscle samples, which may be unsurprising because HOMA-IR is
rather a surrogate marker for hepatic insulin resistance (Matthews et al., 1985; Singh and Saxena, 2010).
Overall, our data are in good agreement with previous studies which have shown a downregulation of mito-
chondrial proteins in skeletal muscles from obese and T2D people (Højlund et al., 2003; Hwang et al., 2010;
Giebelstein et al., 2012; Chae et al., 2018). Reduced gene expression of mitochondrial complex compo-
nents has been observed also in skeletal muscle in people with IGT (Osler et al., 2015; Mootha et al.,
2003). Our study expands these previous observations, as we observed a reduction in mitochondrial pro-
teins already in skeletal muscles from men with IFG. These data suggest that the downregulation of mito-
chondrial proteins precedes the development of hyperglycemia, in agreement with reduced expression of
OXPHOS genes in skeletal muscle from men with IGT (Mootha et al., 2003).
Analysis of skeletal muscle phosphoproteome complements our findings and reveals an enrichment of
altered proteins in signaling pathways regulating glucose metabolic processes, muscle contraction, and
the structure of muscle cells (see Tables S3 and S4 and Figure 6). As examples, basal phosphorylation of
TBC1D1 (at Ser 237) and TBC1D4 (Akt Susbtrate 160) (at Ser 341 and at Thr 568), signaling effectors involved
in insulin and AMPK signaling to GLUT4 translocation and glucose transport (Hatakeyama et al., 2019), was
increased in NGT as compared with T2D muscles, as these phosphorylations were not detected in T2D
muscles (see Table S3 and Figure 6). On the other hand, phosphorylation of myosin light chain 1/3 (at
Thr 65) or troponin T (at Ser 159) was increased in T2D as compared with NGT muscles, as these phosphor-
ylations were not detected in NGTmuscles. Dysregulation in basal phosphorylation of proteins in T2Dmus-
cle is in agreement with the global analysis of phosphoproteome in iPS-cell-derived-induced myoblasts
from T2D donors which has revealed that there are several alterations in basal phosphorylation of proteins
regulating various cellular functions such as RNA metabolism, vesicle-mediated transport, and cell cycle in
T2D (Batista et al., 2020). In our study, alterations in phosphorylation were also evident in muscles frommen
with IFG or IGT, indicating that changes in skeletal muscle proteome are initiated at an early stage during
the development of dysregulation in glucose metabolism. Collectively, our data suggest that reduced
mitochondrial electron transport and oxidative phosphorylation in skeletal muscle may contribute to insu-
lin resistance and may predispose to deterioration of glucose tolerance from normal toward the diabetic
spectrum. These observations highlight the importance of physical activity as an important nonpharma-
ceutical method to improve metabolic health and reduce risk for insulin resistance and T2D, as aerobic
endurance training is associated with many beneficial physiological changes, such as mitochondrial
biogenesis, changes in skeletal muscle proteins involved in energy metabolism, reduced cardiovascular
risk profile, and improved insulin sensitivity (Egan and Zierath, 2013; Hussey et al., 2013; Robinson et al.,
2017).
We had the opportunity to analyze skeletal muscle proteome in biopsies obtained from two men several
years apart. This is a number too low to draw any firm conclusions. However, we observed upregulation
of 20 proteins that were common in both men, likely to be related to aging. Interestingly, JPT1 protein
expression was increased 185-fold in skeletal muscle biopsy from the man with T2D with advancing age.
JPT1 expression has originally been identified in murine hematopoietic and brain cells (Tang et al.,
1997), and JPT1 has been reported to inhibit AKT-GSK3b signaling in cancer cells (Varisli et al., 2011).
AKT-GSK3b signaling is centrally involved in the regulation of insulin action on glycogen synthesis. In
our study, an increase in JPT1 protein expression in type 2 diabetic skeletal muscle over a time period
of 9 years was associated with the deterioration of metabolic control of this individual, as his overall glucose
control had attenuated (HbA1c 5.9% vs 6.8%) despite intensification of his antihyperglycemic treatment.
Thus, increased JPT1 protein expression may have contributed to worsening of glycemic control via
impaired nonoxidative glucose disposal (glycogen synthesis), owing to inhibition of AKT-GSK3b signaling.
Clearly, the potential role of JPT1 in the inhibition of glycogen synthesis and insulin sensitivity in skeletal
muscle needs to be explored in future studies.
Our data set also revealed interesting individual proteins that were uniquely altered in skeletal muscle in




Articlemitochondrial (SUPV3L1) was uniquely downregulated in skeletal muscle biopsies from men with IFG.
SUPV3L1 regulates mitochondrial RNA metabolism and it also unwinds dsDNA (Minczuk et al., 2002;
Szczesny et al., 2010). SUPV3L1 protein expression has been reported to be increased in skeletal muscle
from nondiabetic obese (mean BMI 34.2 vs 25.1 kg/m2) people (Formentini et al., 2017). In our study,
men with NGT (mean BMI 25.7 kg/m2) or IFG (mean BMI 27.3 kg/m2) were of similar BMI. Therefore, our
data suggest that the presence of glucose dysregulation, IFG, results in decreased SUPV3L1 expression.
This may impact mitochondrial RNA metabolism in IFG. SNRPN is a part of the spliceosome. It regulates
pre-mRNA processing and may be involved in tissue-specific alternative splicing (Jing et al., 2015). SNRPN
expression was uniquely downregulated in IGTmuscle, suggesting impairment inmRNAmetabolism in this
condition. Interestingly, analysis of phosphoproteome in iPSC-derived myoblasts reveals a dysregulated
basal phosphorylation of proteins involved in mRNA metabolism and mRNA splicing in T2D (Batista
et al., 2020). Our results suggest that abnormalities in mRNA metabolism are present also in prediabetes.
ATP synthase subunit a (MT-ATP6), NADH dehydrogenase (ubiquinone) complex I, assembly factor 6
(NDUFAF6), and tubulin-folding cofactor B were uniquely downregulated in T2D muscle. ATP synthase
subunit a (MT-ATP6) is a part of the mitochondrial membrane ATP synthase (complex V). This subunit of
complex V contains the pore that releases the proton gradient in the mitochondrial inner membrane. Mu-
tations in MT-ATP6 gene are the most common cause of complex V deficiency and have been described to
lead to several biochemical alterations such as decreased basal respiration, increased ROS, and reduced
ATP synthesis (Ganetzky et al., 2019). NDUFAF6 is crucial in the assembly of mitochondrial NADH:ubiqui-
none oxidoreductase complex (complex I). Knockdown of NDUFAF6 gene, also known asC8orf38, leads to
a profound reduction in complex I abundance and activity, comparable with the knockdown of the known
complex I assembly factor NDUFAF1. Mutation in the NDUFAF6/C8orf38 gene causes an inherited mito-
chondrial complex I deficiency in humans (Leigh syndrome) (Pagliarini et al., 2008, Mckenzie et al., 2011).
Thus, decreased expression of MT-ATP6 and NDUFAF6 in T2D muscle is in agreement with the generally
observed OXPHOS defect in T2D (Højlund et al., 2003; Hwang et al., 2010; Giebelstein et al., 2012; Chae
et al., 2018; Mootha et al., 2003; Patti et al., 2003). Microtubules are a part of the cytoskeletal networks
in the eukaryotic cell. Tubulin-folding cofactor B regulates tubulin synthesis (Tian et al., 1997). Our obser-
vation of the reduced expression of tubulin-folding cofactor B in T2D muscle raises a possibility that the
generation of microtubules is compromised in T2D muscle. Intact microtubule cytoskeleton is required
for example for proper GLUT4 trafficking into plasma membrane and insulin-stimulated glucose uptake
(Fletcher et al., 2000). Thus, reduced tubulin-folding cofactor B may lead to impaired microtubule forma-
tion in skeletal muscle and thus contribute to T2D pathogenesis.Limitations of the study
For the comparison of the proteome in paired muscle biopsies over time, the number of subjects was very
low, allowing only for discovery of tentative associations with aging or worsening of glucosemetabolic con-
trol. Another limitation is that this is a cross-sectional study, and therefore, it remains uncertain whether the
observed progressive reduction in mitochondrial proteins is the cause or the consequence of deterioration
of glucose tolerance from normal, IFG, IGT, to T2D. While there is a consensus on skeletal muscle mito-
chondrial dysfunction in insulin resistance and T2D, it remains much debated if the decrease in mitochon-
drial oxidative metabolism is causal to insulin resistance and diabetic metabolism (Goodpaster, 2013; Hol-
loszy, 2013; Patti and Corvera, 2010; Pinti et al., 2019). For example, a study of subjects with severe insulin
resistance owing to mutations in the insulin receptor suggests that defective insulin signaling may lead to
impaired mitochondrial function in skeletal muscle (Sleigh et al., 2011). On the other hand, excessive exer-
cise training led to impairment in mitochondrial function in skeletal muscle with concomitant decrease in
glucose tolerance (Flockhart et al., 2021). Owing to the descriptive nature of our study, the findings can be
considered exploratory, and there is a need for further mechanistic studies regarding the novel targets with
altered expression between the different glucose tolerance groups. The overall strength of the study is the
large cohort of clinically characterized men. There was a clear decrease in mitochondrial proteins in mus-
cles from men with prediabetes or T2D, which is in agreement with previous studies (Højlund et al., 2003;
Hwang et al., 2010; Giebelstein et al., 2012; Chae et al., 2018). As myoblasts cultured from induced plurip-
otent stem cells from donors with T2D retain the insulin-resistant phenotype and demonstrate key defects
of impaired insulin signaling, glucose uptake, and mitochondrial respiration (Batista et al., 2020), the avail-
able data collectively suggest a tight association between insulin resistance and impaired mitochondrial
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Hälsa Foundation (to HAK), Maud Kuistila Foundation (to HAK), Novo Nordisk Foundation (to HAK), Paulo
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Biological samples
Human skeletal muscle biopsies This paper N/A
Chemicals, peptides and recombinant proteins
UREA Sigma Aldrich Cat#U5378
Ammonium bicarbonate, NH4HCO3 Sigma Aldrich Cat#A6141
Tris(2-carboxyethyl)phosphine Sigma Aldrich Cat#C4706
Iodoacetamide Fluka BioChemica Cat#57670
Sequencing Grade Modified Trypsin Promega Cat#V5113
Formic acid Fluka Cat#56302-10X1ML
Acetonitrile Merck Cat#1000292500
Trifluoroacetic acid Fluka Cat#40967-10x1ml
10% ammonia Fluka Cat#17837
Critical commercial assays
BCA protein assay kit Pierce, Thermo Scientific Cat#23225
iRT-peptide kit Biognosys Ki-3002-2
Software and algorithms
SPSS Statistics IBM version 25
RStudio RStudio Team https://www.rstudio.com/ RStudio version 1.4.1106
R R Core Team https://www.r-project.org/ R version 4.0.54
ProteinPilot software AB SCIEX Paragon algorithm (v4.5)
PeakView AB SCIEX version 2.1 with SWATH quantitation plug-in
MaxQuant Cox and Mann. 2008 version 1.6.0.16
Human Uniprot Database www.uniprot.org release 11_2018 with 20,347 entries
Human Uniprot Database www.uniprot.org release 01_2020 with 20,303 entries
DAVID bioinformatics resources https://david.ncifcrf.gov/ version 6.8
VENNY 2.1 https://bioinfogp.cnb.csic.es/tools/venny/ version 2.1
PhosphoSitePlus www.phosphosite.org version 6.5.9.3
NetworKIN software Horn et al., 2014 version 2.1
Other
FastPrep-24 5G bead homogenizer MP Biomedicals 116005500
Agilent 3100 OFFGEL fractionator Agilent Technologies RRID:SCR_019388
TripleTOF 6600 Quadrupole Time-Of-Flight
instrument
Sciex TripleTOF 6600
Eksigent nanoLC with a Turbo V Source Sciex Turbo V Source
Q Exactive ESI-quadrupole-orbitrap mass
spectrometer
Thermo Fisher Scientific RRID:SCR_020571
EASY-nLC 1000 nanoflow LC Thermo Fisher Scientific RRID:SCR_014993
zirconia beads BioSpec Products 1 mm beads
IPG strips GE Healthcare 24 cm pH 3–10
C18 microspin columns Nest Group HUM S18V
YMC-Triart C18 column YMC 12nm, 3mm, 150x0.3mm
Acclaim PepMap100 Thermo Fisher Scientific 100 mm32cm, 3mm, 100Å
Acclaim PepMap100 Thermo Fisher Scientific 75 mm315cm, 2mm, 100Å






Further information and requests for resources should be directed to the lead contact, Heikki Koistinen
(heikki.koistinen@helsinki.fi), University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Materials availability
This study did not generate new unique reagents.
Data and code availability
Raw mass spectrometry data reported in this study cannot be deposited in a public repository because of
the EU-GDPR regulations. The summary statistics describing these data have been published as supple-
mental tables (Tables S1, S2, and S3) with this paper and are publicly available as of the date of publication.
This paper does not report original code.
Any additional information required to reanalyze the data reported in this paper is available from the lead
contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Subjects
The study protocol was reviewed and approved by the Ethics Committee of the Department of Medicine,
Helsinki University Hospital, and written informed consent was obtained from all subjects before partic-
ipation. The reported investigations have been carried out in accordance with the principles of the
Declaration of Helsinki. We obtained muscle biopsies from 148 men (aged 20–70 years): 24 men with
T2D, 14 men with impaired glucose tolerance (either isolated IGT, or a combination of IFG and IGT),
25 men with impaired fasting glucose (IFG), and 85 men with normal glucose tolerance (NGT) (Table
1). To characterize glucose tolerance (WHO criteria), a standard oral glucose tolerance test (OGTT)
with 75 g glucose was performed on a separate study day (Table 2). Seventeen men had previously
been diagnosed with T2D and did not participate in OGTT. Seven men were found to have a previously
undiagnosed T2D, had not yet received antihyperglycemic treatment, and are considered here as diet-
treated. Overall, the duration of diabetes was 4 G 1 years. T2D was managed with a diet (n=14), met-
formin (n=3), a combination of metformin and DPP4 inhibitor (n=3), a combination of metformin and in-
sulin (n=1), a combination of metformin, sulphonylurea and insulin (n=1), or a combination of metformin,
GLP-1 receptor agonist and insulin (n=1). One man with T2D was studied twice 9 years apart. At the time
of his first examination his weight was 76 kg, BMI 25.2 kg/m2, his T2D was managed with metformin only,
and his HbA1c was 5.9%. At the time of the second study, his weight was 71.5 kg, BMI 24.0 kg/m
2, his
diabetes was managed with a combination of metformin, sulphonylurea, and DPP4 inhibitor, and his
HbA1c was 6.8%. One man with normal glucose tolerance was studied twice 7 years apart. His body
weight (76 vs 75.5 kg), BMI (24.4 vs 24.8 kg/m2), and HbA1c (5 % vs 5.5%) were stable during this periodTable 2. Results of oral glucose tolerance tests
NGT IFG IGT T2D
fB-glucose (mmol/L) (n) 5.1 G 0.06 (24) 5.9 G 0.07 a (10) 5.6 G 0.3 b (4) ND
2h-B-glucose (mmol/L) (n) 4.8 G 0.2 (24) 5.4 G 0.1 (10) 7.3 G 0.3a,c (4) ND
fP-glucose (mmol/L) (n) 5.5 G 0.03 (61) 6.3 G 0.04 a (15) 6.2 G 0.1 a (10) 7.5 G 0.2 a,d,e (7)
2hP-glucose (mmol/L) (n) 5.4 G 0.1 (61) 6.2 G 0.2 (15) 8.8 G 0.3 a,d (10) 11.2 G 1.5 a,d,f (7)
Oral glucose tolerance tests were performed on a day separate frommuscle biopsy. Data are given asmeanG SEM, one-way
ANOVA followed by Sidak’s post hoc test for multiple comparisons.
ap < 0.001 vs NGT.
bp < 0.05 vs NGT.
cp < 0.01 vs IFG.
dp < 0.001 vs IFG.
ep < 0.001 vs IGT.
fp < 0.01 vs IGT.




Article(0 vs 7 years, respectively). Proteomic data for one time point only are reported in the main analysis (Ta-
bles S1 and S2); proteomic data on paired muscle biopsies are shown in Table S5. One man with IFG and
one man with T2D were found to have previously untreated primary hypothyroidism, and one man with
NGT was found to have untreated vitamin B12 deficiency owing to atrophic gastritis at the time of the
biopsy. Analysis of the data set without these 3 samples revealed that changed proteins and associated
biological pathways were essentially the same as in the analysis of the whole cohort. Therefore, data from
these 3 samples are included in this report.
METHOD DETAILS
Muscle biopsy
All men were instructed to avoid strenuous exercise for 72 h before the muscle biopsy. The participants re-
ported to the clinical research unit after an overnight fast, and a venous blood sample was taken from the
antecubital vein. Serum samples were stored at -70 C for subsequent analysis. Muscle biopsies were ob-
tained from vastus lateralis muscle under local anesthesia (5–10 mg/ml lidocaine hydrochloride) (Kuoppa-
maa et al., 2008; Scott et al., 2016). A portion of the biopsy was directly frozen in liquid nitrogen and stored
at -140 C for proteomic analyses.
Sample preparation
20–80 mgmuscle tissue pieces were homogenized in 8.0 M UREA/50 mMNH4HCO3 using FastPrep-24 5G
bead homogenizer (MP Biomedicals) with 1mm zirconia beads (BioSpec Products). Total protein content of
the homogenates was measured using a BCA protein assay kit (Pierce, Thermo Scientific), and 100 mg of
total protein per sample was taken for SWATH analysis and an additional 500 mg from six selected samples,
covering all sample types, for the ion library building. The proteins were reduced with Tris(2-carboxyethyl)
phosphine (TCEP; Sigma Aldrich), alkylated with iodoacetamide, trypsin-digested with Sequencing Grade
Modified Trypsin (Promega) using a 1:100 enzyme:protein ratio at 37C o/n, and then, desalted with C18
microspin columns (Nest Group).
The ion library generation
For themuscle library building, tryptic peptides from six selectedmuscle samples were fractionated with an
Agilent 3100 OFFGEL fractionator (Agilent Technologies), using 24 cm pH 3–10 IPG strips (GE Healthcare).
The strips were focused at a maximum of 8000 V, 50 mA, 200 mW, until 50 kVh was reached. The runs took
approximately 24–36 h. A total of eight fractions per sample were collected, desalted with C18 columns,
and analyzed separately with a TripleTOF 6600 Quadrupole Time-Of-Flight instrument (Sciex) coupled
to an Eksigent nanoLC with a Turbo V Source, working in microspray mode. Reference peptides from
the iRT-kit (Biognosys) were spiked into each fraction. YMC-Triart C18 column (12 nm, 3 mm, 150 x
0.3 mm) was used for peptide separation. The MS analysis was performed in data-dependent acquisition
(DDA) in positive ion mode, using a linear 60-min gradient from 5 to 35 % buffer B (0.1 % formic acid in
acetonitrile). Survey scans were acquired in 250 ms and the top 30 ions above the intensity threshold of
150 counts were selected for subsequent MS/MS scans (100–1500 m/z, 100 ms accumulation time per
MS/MS).
The raw MS data were processed with ProteinPilot software using Paragon algorithm (v4.5, AB SCIEX [Shi-
lov et al., 2007]). Searches were performed against the reviewed human UniProt database (release 11/2018)
supplemented with porcine trypsin and iRT-peptide sequences (total of 20,347 entries). Carbamidomethy-
lation (+57.021 Da) of cysteine residues was used as static modification and oxidation (+15.994 Da) of
methionine was used as dynamic modification. Precursor mass tolerance and fragment mass tolerance
were set to less than 20 ppm and 0.1 Da, respectively. For ProteinPilot search, the ‘‘Thorough ID’’ mode
was selected, which automatically adjusts the mass tolerance to fit the high-resolution MS and MS/MS
data. A maximum of two missed cleavages was allowed and the results were filtered to a maximum false
discovery rate (FDR) of 1%. The resulting human muscle specific spectral library contains 1,140,750 spectra
from 80,041 distinct peptides useful to quantify 3,096 proteins, including iRT reference peptide mix and
trypsin used for digestion.
SWATH analysis and peak extraction
SWATH-MS analysis, a data-independent acquisition method, was performed using the same instrument




Articlewith a variable window width strategy (from 6 to 50 Da). Peptide activation was performed using collision
induced dissociation, using nitrogen as inert gas, with rolling collision energy and 5 eV of energy spread.
The accumulation time was set to 250 ms for MS1 and 100 ms for MS2 scan. The entire duty cycle was
approximately 3.1 s.
Peak extraction of the SWATH data was performed using PeakView (version 2.1) with SWATH quantitation
plug-in (SCIEX). Reference peptides from the iRT-kit (Biognosys) spiked into each sample were used to cali-
brate the retention time of extracted peptide peaks. The settings used were as follows: the maximum num-
ber of peptides per protein, 25; the number of transitions or fragment ions per peptide, 6; a peptide con-
fidence threshold, 90; FDR 1 %; XIC (Extracted Ion Chromatogram) retention time window, 10; m/z
tolerance, 75 ppm; shared and modified peptides were excluded. After SWATH peak extraction, the tran-
sition ion peak areas, peptide peak areas, and protein peak areas were exported in Excel format for further
statistical analysis.
Other determinations
The circumference of the waist was measured to the nearest 0.5 cm midway between the lower rib margin
and the iliac crest, and the circumference of the hip was measured at the level of the trochanters with a soft
measuring tape (Koistinen et al., 2001; Kuoppamaa et al., 2008). Blood glucose concentration (participants
1–50) was analyzed by glucose dehydrogenase method (Precision-G Blood Glucose Testing System, Med-
isense, Abbott, IL, USA), and plasma glucose concentration (participants 51-148) was analyzed by hexoki-
nase method (Roche Modular, F. Hoffman-La Roche Ltd, Rotkreuz, Switzerland). HbA1c was determined by
an immunological method or by high-performance liquid chromatography. Fasting serum insulin concen-
tration was determined by chemiluminescence immunoassay (Liaison XL, DiaSorin, Saluggia, Italy). Fasting
serum glucose; total, HDL, and LDL cholesterol; and triglyceride concentrations were determined by pro-
ton NMRmetabolomics (Nightingale Health Ltd, Helsinki, Finland) (Locke et al., 2019). Homeostatic model
assessment of insulin resistance (HOMA-IR) was calculated from fasting serum glucose and insulin concen-
trations by the formula: HOMA-IR = ðglucose x insulinÞ22:5 (Matthews et al., 1985; Singh and Saxena, 2010).
Mass spectrometry analysis of phosphorylation sites
For phosphoproteomics analysis, 300 mg of total protein per sample was digested, as described previously.
Phosphopeptide enrichment was performed using immobilized metal ion affinity chromatography with ti-
tanium (IV) ion (Ti4+-IMAC). The IMAC material was prepared and used essentially as described (Zhou
et al., 2013). Briefly, Ti4+-IMAC beads were loaded onto GELoader tips (Thermo Fisher Scientific). The pro-
tein digests were dissolved in a loading buffer (80% ACN, 6% trifluoroacetic acid) and added into the spin
tips. The columns were washed and the bound phosphopeptides were eluted with 10% ammonia, followed
by purification with C18 microspin columns before LC-MS/MS analysis.
The LC-MS/MS analysis of phosphorylated peptides was performed on a Q Exactive ESI-quadrupole-orbi-
trap mass spectrometer coupled to an EASY-nLC 1000 nanoflow LC (Thermo Fisher Scientific), using Xca-
libur version 3.1.66.10 (Thermo Fisher Scientific). The C18-packed precolumn (Acclaim PepMap100,
100 mm32 cm, 3 mm, 100 Å; Thermo Fisher Scientific) and the C18-packed analytical column (Acclaim
PepMap100, 75 mm315 cm, 2 mm, 100 Å) were used. The phosphopeptides were separated by a 120-
min linear gradient. The total measurement time was 140 min per sample. The mass spectrometry analysis
was performed as DDA in positive-ion mode. MS spectra were acquired from m/z 300 to m/z 2000 with a
resolution of 70,000, with full AGC target value of 3,000,000 ions and a maximal injection time of 120 ms
in profile mode. The tenmost abundant ions with charge states from 2+ to 7+ were selected for subsequent
fragmentation (HCD), and MS/MS spectra were acquired with a resolution of 17,500, with an AGC target
value of 5000, a maximal injection time of 120 ms and the lowest mass fixed at m/z 120 in centroid
mode. Dynamic exclusion duration was 30 s. Six fully independent replicates were performed for each
glucose tolerance category.
Raw data were processed withMaxQuant version 1.6.0.16 (Cox andMann, 2008) against the human compo-
nent of the Uniprot Database (release 01_2020 with 20,303 entries) using the Andromeda search engine
(Cox et al., 2011). Carbamidomethylation (+57.021 Da) of cysteine residues was used as static modification.
Phosphorylation of serine/threonine/tyrosine (+79.966 Da) and oxidation (+15.994 Da) of methionine were
used as dynamic modification. Precursor mass tolerance and fragment mass tolerance were set to less than




Articlefiltered to a maximum FDR of 0.05 and further based on the phosphorylation localization probability at the
cutoff value of 0.75 with exception of two adjacent sites where the cutoff value was 0.5. Student’s t-test was
used to detect statistically significant changes between sample groups, and differences with p-value < 0.05
were considered significant. In the comparison analysis, detection of two phosphosites of six replicates was
demanded.
Functional annotations
Gene Ontology annotations were obtained from DAVID bioinformatics resources (Huang et al., 2009;
Huang et al., 2008). Pathway analysis was performed by mapping the proteins with significantly altered
expression levels with pathways in the Kyoto Encyclopedia of Genes and Genomes database. Comparisons
between datasets were calculated using VENNY 2.1 online tool (https://bioinfogp.cnb.csic.es/tools/venny/
). Identified phosphorylation sites and substrates were compared to kinase-substrate data extracted from
PhosphoSitePlus (v6.5.9.3; www.phosphosite.org). Kinase prediction was made using NetworKIN soft-
ware (Horn et al., 2014).
QUANTIFICATION AND STATISTICAL ANALYSIS
The clinical data are given as meanGSEM (Tables 1 and 2). Potential differences in clinical variables be-
tween the study groups were analyzed by one-way ANOVA followed by Sidak’s post hoc test for multiple
comparisons (IBM SPSS Statistics, version 25).
Proteomics data were analyzed with RStudio version 1.4.1106 (RStudio Team, 2020) running with R version
4.0.54 (R Core Team, 2014). The data were separated to two data sets: one containing only the data from
men that were sampled twice (Table S5) and one for the main comparison between the different glucose
tolerance groups (main data set, Tables S1 and S2). The earlier muscle samples of the twice-sampled men
were removed from the main dataset. The following steps were performed separately on these two data
sets.
The protein peak areas were normalized by total area normalization: the sums of protein peak areas for
each sample were calculated, and the normalization coefficient for each sample was the maximum of these
summed protein peak areas divided by the total peak area of the corresponding sample. The missing
values, 30 in total in the main data set and none in the other, were imputed with k nearest neighbors impu-
tation (kNN, k = 10). Finally, the data were log2 transformed.
One-way ANOVA was used for protein abundance comparison across the different glucose tolerance
groups (Results, figure legends 2-4, and 7; and Tables S1 and S2). The ANOVA p-values were multiple hy-
pothesis corrected with FDR (Benjamini-Hochberg) correction, and the proteins for which q-value < 0.05
were subjected to Dunnett’s post hoc test with the NGT group as the reference group. The p-values
from the post hoc test were FDR corrected, and proteins with q-value < 0.05 were considered significantly
differentially expressed. Fold changes were calculated using arithmeticmeans of the log2 transformed pro-
tein intensities.
For hierarchical clustering (Figure 2) and principal component analysis (PCA, Figure S1), the log2-trans-
formed data was scaled and centered to mean 0 and variance 1. Hierarchical clustering was performed
with Euclidean distance metric and complete linkage.
When analyzing the effect of glucose tolerance status on phosphoproteome (Figure 6 and Table S3), 2-
sided t-tests with Welch approximation for unequal variances were used and differences with a p-value <
0.05 were considered significant.
Fold-changes for the twice-sampled men’s proteomes were calculated using arithmetic means of the log2
transformed protein intensities. For the pairwise comparison of protein abundance between two individual
samples, statistical testing could not be performed, and therefore, only fold change > 5 was used as a
tentative criterion of significance (see Table S5).
Multiple linear regression was used to estimate the effect of the following clinical parameters on protein
intensities: subjects glucose tolerance status, age, log2-HOMA-IR and physical activity level. In order to es-




Articlegraded as sedentary (0= no reported physical activity, or 1= walking) or physically active (more strenuous
physical activity than walking: 2= 30 min–4 h per week, and 3= more than 4 h per week) as per their self-
reported physical activity. Glucose tolerance status was dummy coded as follows: 0=NGT; 1=IFG;
2=IGT; 3=T2D. Normalized, log2 transformed protein intensities were used. FDR multiple hypothesis
correction was used separately for each clinical variable, and q-values lower than 0.05 were considered sig-
nificant. Detailed results of the regression analysis are presented in Table S6.22 iScience 24, 102712, July 23, 2021
